Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.96 USD | -0.13% | -4.47% | -21.06% |
Financials (USD)
Sales 2024 * | 29.08M | Sales 2025 * | 2.68M | Capitalization | 849M |
---|---|---|---|---|---|
Net income 2024 * | -199M | Net income 2025 * | -297M | EV / Sales 2024 * | 11 x |
Net cash position 2024 * | 528M | Net cash position 2025 * | 356M | EV / Sales 2025 * | 184 x |
P/E ratio 2024 * |
-4.25
x | P/E ratio 2025 * |
-3.23
x | Employees | 124 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.28% |
Latest transcript on Zentalis Pharmaceuticals, Inc.
1 day | -0.13% | ||
1 week | -4.47% | ||
Current month | +8.14% | ||
1 month | -7.14% | ||
3 months | -7.79% | ||
6 months | +6.60% | ||
Current year | -21.06% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 20-06-30 | |
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 22-10-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Karan Takhar
BRD | Director/Board Member | 32 | 17-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.07% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 11.96 | -0.13% | 370,523 |
24-05-15 | 11.98 | +2.61% | 589,889 |
24-05-14 | 11.67 | -0.68% | 504,707 |
24-05-13 | 11.75 | -6.30% | 665,954 |
24-05-10 | 12.54 | +0.16% | 620,927 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.06% | 850M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- ZNTL Stock